PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients

The development of small molecules able to block specific or multiple isoforms of phosphoinositide 3-kinases (PI3K) has already been an active field of research for many years in the cancer field. PI3Kδ inhibitors are among the targeted agents most extensively studied for the treatment of lymphoma p...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2021-11, Vol.13 (21), p.5535
Main Authors: Tarantelli, Chiara, Argnani, Lisa, Zinzani, Pier Luigi, Bertoni, Francesco
Format: Article
Language:English
Subjects:
1-Phosphatidylinositol 3-kinase
Antigens
Antitumor agents
Apoptosis
Cancer
Cytokines
Cytotoxicity
Immune response
Immune system
Immunomodulation
Immunosuppressive agents
Isoforms
Kinases
Ligands
Lymphatic system
Lymphocytes T
Lymphoma
Medical prognosis
Patients
Review
Tumor microenvironment
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The development of small molecules able to block specific or multiple isoforms of phosphoinositide 3-kinases (PI3K) has already been an active field of research for many years in the cancer field. PI3Kδ inhibitors are among the targeted agents most extensively studied for the treatment of lymphoma patients and PI3Kδ inhibitors are already approved by regulatory agencies. More recently, it became clear that the anti-tumor activity of PI3K inhibitors might not be due only to a direct effect on the cancer cells but it can also be mediated via inhibition of the kinases in non-neoplastic cells present in the tumor microenvironment. T-cells represent an important component of the tumor microenvironment and they comprise different subpopulations that can have both anti- and pro-tumor effects. In this review article, we discuss the effects that PI3Kδ inhibitors exert on the immune system with a particular focus on the T-cell compartment.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers13215535